PHARMACY MARKET

Pharma R&D Annual Review

March 15, 2022

Pharma R&D
Successes in 2021 – New active substance
drug launches

Spotlight

Development Center for Biotechnology

The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals"​. This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies.

OTHER WHITEPAPERS
news image

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Read More
news image

How to optimize clinical supply chain management with Slope

whitePaper | December 15, 2022

Successful execution of clinical trials requires the orchestration of multiple moving parts, with everything from protocol design and patient visit schedules, to lab kits and biological samples needing to seamlessly line up to ensure on-time, on-budget delivery of high-quality data.

Read More
news image

Expediting early-phasedevelopment ofsmall molecules: Anintegrated approach

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).

Read More
news image

Market Access Trends in the US, Europe, and Emerging Markets

whitePaper | November 14, 2022

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets.

Read More
news image

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Read More
news image

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More

Spotlight

Development Center for Biotechnology

The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals"​. This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies.

Events